Tumor angiogenesis as prognostic and predictive marker for chemotherapy dose-intensification efficacy in high-risk breast cancer patients within the WSG AM-01 trial

Autor: Ronald E. Kates, Christopher Poremba, Raihanatou Diallo-Danebrock, U. Nitz, E. Ting, Svjetlana Mohrmann, Oleg Gluz, Heiko Mendrik, Cornelia Liedtke, Verena Artinger, Andreas Gaumann, Arndt Hartmann, Peter J. Wild, Nadia Harbeck, Elisabeth Ehm
Přispěvatelé: West German Study Group, Department of Gynecology and Obstetrics, Bethesda Clinics Wuppertal, Institute of Pathology, Universität Regensburg (UR), Universität Zürich [Zürich] = University of Zurich (UZH), University Hospital Münster - Universitaetsklinikum Muenster [Germany] (UKM), Heinrich Heine Universität Düsseldorf = Heinrich Heine University [Düsseldorf], Institute of Histopathology, Cytology and Molecular Pathology Trier, Breast Centre, University of Cologne, Friedrich-Alexander Universität Erlangen-Nürnberg (FAU), Institute of pathology, University of Zurich, Gaumann, A
Jazyk: angličtina
Rok vydání: 2011
Předmět:
Oncology
Cancer Research
Pathology
medicine.medical_treatment
High-risk breast cancer
0302 clinical medicine
High-dose chemotherapy
Cluster Analysis
1306 Cancer Research
0303 health sciences
Univariate analysis
Predictive marker
Neovascularization
Pathologic
Endoglin
Middle Aged
Prognosis
Immunohistochemistry
3. Good health
Gene Expression Regulation
Neoplastic
Platelet Endothelial Cell Adhesion Molecule-1
030220 oncology & carcinogenesis
2730 Oncology
Female
Breast disease
Adult
medicine.medical_specialty
Molecular subtypes
Context (language use)
610 Medicine & health
Antineoplastic Agents
Breast Neoplasms
Receptors
Cell Surface
Disease-Free Survival
03 medical and health sciences
Breast cancer
Antigens
CD
Internal medicine
10049 Institute of Pathology and Molecular Pathology
medicine
Biomarkers
Tumor
Humans
030304 developmental biology
Chemotherapy
business.industry
Cancer
medicine.disease
Multivariate Analysis
Angiogenesis
business
Zdroj: Breast Cancer Research and Treatment
Breast Cancer Research and Treatment, Springer Verlag, 2011, 126 (3), pp.643-651. ⟨10.1007/s10549-011-1377-6⟩
ISSN: 0167-6806
1573-7217
DOI: 10.1007/s10549-011-1377-6⟩
Popis: International audience; The goal of this analysis was to characterize the survival impact of angiogenesis in the patients with high-risk breast cancer, particularly the predictive impact on benefit from dose intensification of adjuvant chemotherapy. Formalin-fixed tissue sample of 152 patients treated as part of the WSG AM-01 trial by either high-dose or conventional dose-dense chemotherapy were analyzed. Angiogenic activity was measured using microvessel count and vascular surface area (VSA) determined by the expression of vascular markers CD31 ( = 128) and CD105/endoglin ( = 130). Protein molecular breast cancer subclasses were analyzed by -means clustering ( = 5). The univariate impact of factors on event-free (EFS) and overall survival (OS) was tested by log-rank statistics and quantified by univariate Cox analysis. Multivariate survival analysis included factors significant in univariate analysis, as well as interactions was performed for EFS. Both VSA/CD31 ( = 0.004) and VSA/CD105 ( = 0.003) were significantly higher among cases with increased Ki-67. A significant association with molecular subtypes was also found for VSA/CD105: in patients with basal-like/Her-2 subtypes, mean was 1.72 versus 1.24 in patients with other subtypes (
Databáze: OpenAIRE
Externí odkaz: